Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans
Executive Summary
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.
You may also be interested in...
Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin
Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.
Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?
The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.
Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says
Agency favors symptom-focused assessments over global quality-of-life evaluations when considering whether the data can support a drug labeling claim for use in treating pediatric cancer. Measures used for EU reimbursement considerations are usually not sufficient for FDA labeling claims, official cautions.